


Korean startup Standigm to open synthetic research centre for drug development

05 July 2021 | News

SK Chemicals-Standigm will collaborate for the development of Standigm's AI-driven drug candidate



South Korea-based startup Standigm Inc. and SK Chemicals have announced that they have signed a strategic partnership contract for collaboration regarding clinical development of Standigm's AI-driven drug candidate for non-alcoholic steatohepatitis (NASH) and the foundation of Standigm's Synthesis Research Center within the headquarters of SK Chemicals.

This partnership was made in conjunction with SK Chemicals' participation in Standigm's pre-IPO round of fundraising.

Under the contract, SK Chemicals will collaborate with Standigm on the clinical development of the NASH drug candidate discovered by Standigm Insight™, an AI-aided drug-repurposing platform, which is expected to enter clinical stage next year.

Moreover, Standigm plans to open its Synthesis Research Center in the headquarters of SK Chemicals next month. Standigm will be able to synthesize its AI-driven drug candidates directly and efficiently.